Platelet-activating factors are associated with cognitive deficits in depressed coronary artery disease patients: a hypothesis-generating study

Journal of Neuroinflammation

Krista L Lanctôt³  Steffany AL Bennett⁴  Paul I Oh³  Daniel Figeys⁴  Hongbin Xu⁴  Nathan Herrmann²  Graham Mazereeuw¹ 

[1] Canadian Institutes of Health Research Training Program in Neurodegenerative Lipidomics, Ottawa, ON, Canada;Department of Psychiatry, University of Toronto, Toronto, ON, Canada;UHN Toronto Rehabilitation Institute, Toronto, ON, Canada;Ottawa Institute of Systems Biology and Neural Regeneration Laboratory, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada

关键词: platelet-activating factor;    neurodegeneration;    memory;    lipidomics;    inflammation;    executive function;    depression;    coronary artery disease;    cognition;    Biomarker;   

Others  :  1151347
DOI  :  10.1186/1742-2094-11-119

 received in 2014-01-30, accepted in 2014-06-20,  发布年份 2014

【 摘 要 】

Background

Patients with coronary artery disease (CAD) are at risk of accelerated cognitive decline, particularly those with major depression. Mechanisms for cognitive deficits associated with CAD, and the effects of depression, remain poorly understood. However, CAD is associated with inflammatory processes that have been linked to neurodegeneration, may contribute to cognitive decline, and are elevated in depression. Platelet-activating factors (PAFs) are emerging as key lipid mediators that may be central to those processes and highly relevant to cognitive decline in CAD.

Methods

This cross-sectional study investigated relationships between various PAFs and cognitive performance in 24 patients with CAD (age, 60.3 ± 9.4; 70.8% male). Analyses were repeated in a subgroup of 15 patients with CAD with major depression (DSM-IV). Cognitive performance was assessed using a standardized battery and summary z scores were calculated based on age, sex, and education norms. Global cognitive performance was the average of domain-specific z scores. Plasma PAF analyses were performed using electrospray ionization mass spectrometry (precursor ion scan).

Results

A greater abundance of PAF PC(O-18:0/2:0) was associated with poorer global cognitive performance in patients with CAD (r = -0.45, P = 0.03). In the major depressed subgroup, PAF PC(O-18:0/2:0) (r = -0.59, P = 0.02) as well as PC(O-16:0/2:0) (r = -0.52, P = 0.04), and lyso-PAF PC(O-16:0/0:0) (r = -0.53, P = 0.04) were associated with poorer global cognitive performance. A greater abundance of PAF PC(O-19:5/2:0) was associated with better global cognitive performance (r = 0.55, P = 0.03), suggesting a possible compensatory species.

Conclusions

This study suggests that certain PAFs might be associated with global cognitive performance in patients with CAD, with stronger relationships observed in those with major depression. Confirmation of these preliminary findings is warranted.

【 授权许可】

   
2014 Mazereeuw et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Eggermont LHP, de Boer K, Muller M, Jaschke AC, Kamp O, Scherder EJA: Cardiac disease and cognitive impairment: a systematic review. Heart 2012, 98:1334-1340.
• [2]Roberts RO, Knopman DS, Geda YE, Cha RH, Roger VL, Petersen RC: Coronary heart disease is associated with non-amnestic mild cognitive impairment. Neurobiol Aging 2010, 31:1894-1902.
• [3]van Exel E, de Craen AJM, Remarque EJ, Gussekloo J, Houx P, Bootsma-van der Wiel A, Frolich M, Macfarlane PW, Blauw GJ, Westendorp RGJ: Interaction of atherosclerosis and inflammation in elderly subjects with poor cognitive function. Neurology 2003, 61:1695-1701.
• [4]Zheng L, Mack WJ, Chui HC, Heflin L, Mungas D, Reed B, DeCarli C, Weiner MW, Kramer JH: Coronary artery disease is associated with cognitive decline independent of changes on magnetic resonance imaging in cognitively normal elderly adults. J Am Geriatr Soc 2012, 60:499-504.
• [5]Lipnicki DM, Sachdev PS, Crawford J, Reppermund S, Kochan NA, Trollor JN, Draper B, Slavin MJ, Kang K, Lux O, Mather KA, Brodaty H: Risk factors for late-life cognitive decline and variation with age and sex in the Sydney Memory and Ageing Study. PloS ONE 2013, 8:e65841.
• [6]Freiheit EA, Hogan DB, Eliasziw M, Patten SB, Demchuk AM, Faris P, Anderson T, Galbraith D, Parboosingh JS, Ghali WA, Knudtson M, Maxwell CJ: A dynamic view of depressive symptoms and neurocognitive change among patients with coronary artery disease. Arch Gen Psychiatry 2012, 69:244-255.
• [7]Gao Y, Huang C, Zhao K, Ma L, Qiu X, Zhang L, Xiu Y, Chen L, Lu W, Huang C, Tang Y, Xiao Q: Depression as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. Int J Geriatr Psychiatry 2013, 28:441-449.
• [8]Swardfager W, Herrmann N, Marzolini S, Oh PI, Saleem M, Shammi P, Kiss A, Cappell J, Lanctot KL: Verbal memory performance and completion of cardiac rehabilitation in patients with coronary artery disease. Psychosom Med 2011, 73:580-587.
• [9]O’Donnell M, Teo K, Gao P, Anderson C, Sleight P, Dans A, Marzona I, Bosch J, Probstfield J, Yusuf S: Cognitive impairment and risk of cardiovascular events and mortality. Eur Heart J 2012, 33:1777-1786.
• [10]Dowlati Y, Herrmann N, Swardfager WL, Reim EK, Lanctot KL: Efficacy and tolerability of antidepressants for treatment of depression in coronary artery disease: a meta-analysis. Can J Psychiatry 2010, 55:91-99.
• [11]Blumenthal JA, Sherwood A, Babyak MA, Watkins LL, Smith PJ, Hoffman BM, O’Hayer CV, Mabe S, Johnson J, Doraiswamy PM, Jiang W, Schocken DD, Hinderliter AL: Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results From the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. J Am Coll Cardiol 2012, 16:1053-1063.
• [12]Delrieu J, Piau A, Caillaud C, Voisin T, Vellas B: Managing cognitive dysfunction through the continuum of Alzheimer’s disease: role of pharmacotherapy. CNS Drugs 2011, 25:213-226.
• [13]Bennett SAL, Valenzuela N, Xu H, Franko B, Fai S, Figeys D: Using neurolipidomics to identify phospholipid mediators of synaptic (dys)function in Alzheimer’s disease. Front Physiol 2013, 4:168.
• [14]Agostinho P, Cunha RA, Oliveira C: Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer’s disease. Curr Pharm Des 2010, 16:2766-2778.
• [15]Stapelberg NJC, Neumann DL, Shum DHK, McConnell H, Hamilton-Craig I: A topographical map of the causal network of mechanisms underlying the relationship between major depressive disorder and coronary heart disease. Aust N Z J Psychiatry 2011, 45:351-369.
• [16]Baune BT, Stuart M, Gilmour A, Wersching H, Heindel W, Arolt V, Berger K: The relationship between subtypes of depression and cardiovascular disease: a systematic review of biological models. Transl Psychiatry 2012, 13:e92.
• [17]Moylan S, Maes M, Wray NR, Berk M: The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatry 2013, 18:595-606.
• [18]Ryan SD, Harris CS, Carswell CL, Baenziger JE, Bennett SAL: Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons. J Lipid Res 2008, 49:2250-2258.
• [19]Mazereeuw G, Herrmann N, Bennett SAL, Swardfager W, Xu H, Valenzuela N, Fai S, Lanctôt KL: Platelet activating factors in depression and coronary artery disease: a potential biomarker related to inflammatory mechanisms and neurodegeneration. Neurosci Biobehav Rev 2013, 37:1611-1621.
• [20]Ryan SD, Whitehead SN, Swayne LA, Moffat TC, Hou W, Ethier M, Bourgeois AJG, Rashidian J, Blanchard AP, Fraser PE, Park DS, Figeys D, Bennett SAL: Amyloid-β42 signals tau hyperphosphorylation and compromises neuronal viability by disrupting alkylacylglycerophosphocholine metabolism. Proc Natl Acad Sci USA 2009, 106:20936-20941.
• [21]Hachinski V, Iadecola C, Petersen RC, Breteler MM, Nyenhuis DL, Black SE, Powers WJ, DeCarli C, Merino JG, Kalaria RN, Vinters HV, Holtzman DM, Rosenberg GA, Wallin A, Dichgans M, Marler JR, Leblanc GG: National Institute of Neurological Disorders and Stroke - Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke 2006, 37:2220-2241. A published erratum appears in Stroke 2007, 38(3):1118
• [22]Benedict R: Brief Visuospatial Memory Test-Revised: Professional Manual. Lutz, FL: Psychological Assessment Resources, Inc.; 1997.
• [23]Hamilton A: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56-62.
• [24]First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV diagnoses (SCID): Clinician and Research Versions. New York, NY: Biometrics Research Department, Columbia University; 1996.
• [25]Bligh EC, Dyer WJ: A rapid method of lipid extraction and purification. Can J Biochem 1959, 37:911-917.
• [26]Xu H, Valenzuela N, Fai S, Figeys D, Bennett SAL: Targeted lipidomics: advances in profiling lysophosphocholine and platelet activating factor second messengers. FEBS J 2013, 280:5652-5667.
• [27]Whitehead SN, Hou W, Ethier M, Smith JC, Bourgeois A, Denis R, Bennett SAL, Figeys D: Identification and quantitation of changes in the platelet activating factor family of glycerophospholipids over the course of neuronal differentiation by high-performance liquid chromatography electrospray ionization tandem mass spectrometry. Anal Chem 2007, 79:8539-8548.
• [28]Blanchard AP, McDowell GSV, Valenzuela N, Xu H, Gelbard S, Bertrand M, Slater GW, Figeys D, Fai S, Bennett SAL: Visualization and Phospholipid Identification (VaLID): online integrated search engine capable of identifying and visualizing glycerophospholipids with given mass. Bioinformatics 2013, 29:284-285.
• [29]Tang C-H, Tsao P-N, Chen C-Y, Shiao M-S, Wang W-H, Lin C-Y: Glycerophosphocholine molecular species profiling in the biological tissue using UPLC/MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2011, 879:2095-2106.
• [30]Fahy E, Cotter D, Sud M, Subramaniam S: Lipid classification, structures and tools. Biochim Biophys Acta 1811, 2011:637-647.
• [31]Blacker D, Lee H, Muzikansky A, Martin EC, Tanzi R, McArdle JJ, Moss M, Albert M: Neuropsychological measures in normal individuals that predict subsequent cognitive decline. Arch Neurol 2007, 64:862-871.
• [32]McDermott LM, Ebmeier KP: A meta-analysis of depression severity and cognitive function. J Affect Disord 2009, 119:1-8.
• [33]Alexopoulos GS: The vascular depression hypothesis: 10 years later. Biol Psychiatry 2006, 60:1304-1305.
• [34]Brookes RL, Herbert V, Paul S, Hannesdottir K, Markus HS, Morris RG: Executive dysfunction, awareness deficits and quality of life in patients with cerebral small vessel disease: a structural equation model. Neuropsychology 2014, 28:247-253.
• [35]Kearney FC, Harwood RH, Gladman JRF, Lincoln N, Masud T: The relationship between executive function and falls and gait abnormalities in older adults: a systematic review. Dement Geriatr Cogn Disord 2013, 36:20-35.
• [36]Stoehr GP, Lu S-Y, Lavery L, Bilt JV, Saxton JA, Chang C-CH, Ganguli M: Factors associated with adherence to medication regimens in older primary care patients: the Steel Valley Seniors Survey. Am J Geriatr Pharmacother 2008, 6:255-263.
• [37]Taylor WD, Aizenstein HJ, Alexopoulos GS: The vascular depression hypothesis: mechanisms linking vascular disease with depression. Mol Psychiatry 2013, 18:963-974.
• [38]Chang HH, Lee IH, Gean PW, Lee S-Y, Chi MH, Yang YK, Lu R-B, Chen PS: Treatment response and cognitive impairment in major depression: association with C-reactive protein. Brain Behav Immun 2012, 26:90-95.
• [39]Grassi-Oliveira R, Bauer ME, Pezzi JC, Teixeira AL, Brietzke E: Interleukin-6 and verbal memory in recurrent major depressive disorder. Neuro Endocrinol Lett 2011, 32:540-544.
• [40]Krogh J, Benros ME, Jørgensen MB, Vesterager L, Elfving B, Nordentoft M: The association between depressive symptoms, cognitive function, and inflammation in major depression. Brain Behav Immun 2014, 35:70-76.
• [41]Bou Khalil M, Hou W, Zhou H, Elisma F, Swayne LA, Blanchard AP, Yao Z, Bennett SAL, Figeys D: Lipidomics era: accomplishments and challenges. Mass Spectrom Rev 2010, 29:877-929.